Repros Therapeutics, Inc.
http://www.reprosrx.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Repros Therapeutics, Inc.
Tech Transfer Roundup: How Can Translational Research Help With The Next Pandemic?
Seven international translational research bodies recommend five actions to help better prepare for future outbreaks. Plus an overview of recent COVID-19-focused collaborations.
Finance Watch: Venture Capital Drives Record-Breaking Year For Cell And Gene Therapies
Private Company Edition: Recent VC financings across biopharma sectors include three major mega-rounds as Generate Biomedicines bringing in $370m, followed by $250m for Acelyrin and $125m for Chroma Medicine. Also, Treadwell raised a $91m series B and Ncardia brought in $60m-plus.
Calithera Drops Development Of Lead Candidate Telaglenastat
Calithera’s most advanced oncological asset, telaglenastat, has failed in yet another indication, prompting the company to fall back on candidates in-licensed from Takeda just last month.
Asia Deal Watch: I-Mab Partners With Sinopharm As It Readies First Regulatory Filing
I-Mab sets commercial plans with Sinopharm for felzartamab in multiple myeloma. Legochem and Antengene team up on antibody-drug conjugates, Luoxin licenses respiratory drug from Marinomed.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Zonagen, Inc.